During August, the registered number of shares and votes in Saniona AB (“Saniona”) has increased due to a set-off new issue of shares resolved by the board of directors on August 15, 2023. As of August 31, 2023, the registered number of shares and votes in Saniona amounts to 64,126,978.
For more information, please contact
Thomas Feldthus, CEO, +45 22109957; [email protected]
About Saniona
Saniona is a clinical-stage biopharmaceutical company focused on the discovery and development of medicines modulating ion channels. Saniona’s most advanced candidate, tesofensine, has progressed towards regulatory approval for obesity by Saniona’s partner Medix. Saniona is advancing four product candidates including Tesomet™ and three ion channel modulators SAN711, SAN903 and SAN2219. Tesomet™ has progressed to mid-stage clinical trials for rare eating disorders. SAN711 has completed Phase 1 for neuropathic pain conditions. SAN903 is ready for Phase 1 for inflammatory and fibrotic disorders. SAN2219 is in preclinical development for epilepsy. Saniona has research and development partnerships with Boehringer Ingelheim GmbH, Productos Medix, S.A de S.V, AstronauTx Limited and Cephagenix ApS. Saniona is based in Copenhagen, and listed on Nasdaq Stockholm Small Cap (OMX: SANION). Read more at www.saniona.com.
This information is information that Saniona AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2023-08-31 07:45 CEST.
Tilaa uutiskirjeemme ja saat uusimmat uutiset, päivitykset ja sisältönostot suoraan sähköpostiisi.